Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remission status in ulcerative colitis patients treated with 5-ASA
2022-001683-10Phase 4Completed
- Sponsor
- Bird
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Salcrozine and 5-aminosalicylic acid + sulphasalazine in autoimmune colitis, sponsored by Bird. Primary endpoint: Percentage of different remission levels. Started Aug 2022; status: completed.
02
Drugs
Salcrozine5-aminosalicylic acid + sulphasalazine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-001683-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001683-10.